Skip to content

Public FDA record

Z-2074-2021: Philips Respironics V60 Plus Ventilator with Software Versions 3.00 and 3.10. The Respironics V60/V60 Pl

Recall record Z-2074-2021 for Respironics California, LLC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2074-2021
Company in FDA record
Respironics California, LLC
FDA record creation date
Jul 22, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class I

Reason stated in the source

It has been identified that ventilators equipped with High Flow Therapy (Software Versions 3.00 and 3.10), that includes a designed safety mechanism that limits the amount of pressure that can be delivered to a patient, in situations where the system pressure reaches the maximum limit and sounds the "Cannot Reach Target Flow" alarm , the system will reduce pressure and simultaneously decreasing the flow rate to a level below what was set by the clinicians. If the reason for the increase in pressure is not resolved, the ventilator will continue to provide the lower flow rate, which result in patients experiencing oxygen desaturation which can be characterized as moderate or severe hypoxemia.

Source facts

Action
On 06/18/2021, the Recalling Firm sent an "URGENT - Medical Device Recall" Notification Letter via USPS certified mail to customers informing them that a problem has been detected in their ventilators that could pose a risk to patients or users. All units with High Flow Therapy option (Software Versions 3.00 and 3.10) are impacted. These ventilators with the High Flow Therapy software were designed with a safety mechanism to limit the amount of pressure that can be delivered to the patient when the ventilator is operating in High Flow Therapy. In situations where the high flow therapy pressure reaches the maximum limit, the ventilator will sound a low priority "Cannot Reach Target Flow (CRTF) alarm and reduces the pressure which also simultaneously decreases the flow rate to a level below what was set by the clinician for as long as the condition persists. Customers are instructed/informed to: When administering HFT via High Flow Nasal Cannula the following action must be taken: (1) Monitor the patients SpO2 continuously; (2) All patients that are dependent on supplemental oxygen, and at risk of clinical deterioration should be under constant and close monitoring by the clinician to prevent dangerous drops in blood oxygen levels, work of breathing and respiratory distress and resulting escalation in medical treatment (3) Respond to all alarms urgently, regardless of alarm priority; (4) If the patient cannot be constantly and closely monitored by the clinician, do not use High Flow Therapy. In addition; (5) Refer to and follow the attached user manual addendum titled V60 Plus User Manual Addendum: High-Flow Therapy Safety and Alarm Features. This user manual addendum provides additional technical details about the CRTF alarm functionality. The addendum is also available at www.philips.com/hrcmanuals under the V60/V60 Plus link titled "V60 Plus User Manual Addendum - High-Flow Therapy Safety and Alarm Features. For additional information and educ
Initiated
2021-06-18
Root cause
Device Design
Distribution
Worldwide Distribution: U.S (nationwide) to states of.: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SC, TN, TX, UT, VA, VT, WA, WI, WV, and WY; and O.U.S. countries of: Andorra, United Arab Emirates, Albania, Argentina, Austria, Australia, Belgium, Canada, Switzerland, Chile, China, Colombia, Czech Republic, Germany, Denmark, Spain, Finland, France, United Kingdom, French Guiana, Guadeloupe, Greece, Hong Kong, Indonesia, Ireland, India, Iceland, Italy, Jordan, Kenya, Kuwait, Lebanon, Latvia, Libya, Morocco, Martinique, Malta, Mexico, Malaysia, New Caledonia, Nigeria, Netherlands, Norway, New Zealand, Philippines, Poland, Portugal, Qatar, R¿union, Russian Federation, Saudi Arabia, Sweden, Singapore, Slovenia, Thailand, and South Africa.
Recall number
Z-2074-2021
Recall status
Open, Classified
CDRH record ID
187952
FDA record created
2021-07-22
Recall event number
88127

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗